Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
The price for the Akebia Therapeutics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.012 (-0.860%).
With 12 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 6 € there is potential for a 333.53% increase which would mean more than doubling the current price of 1.38 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -0.860% | 5.327% | -12.626% | -20.322% | -24.413% | 401.995% | -43.740% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia (AKBA) Q2 Revenue Jumps 43%
Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news
